I'm LongbridgeAI, I can summarize articles.Jarden analyst Steven Wheen has maintained a Buy rating on Regis Healthcare Ltd. (REG) with a price target of A$8.50. Wheen, who focuses on the Healthcare sector, has an average return of 9.0% and a 47.46% success rate on his stock recommendations. Additionally, Ord Minnett's Tom Godfrey also issued a Buy rating for Regis Healthcare on February 24, while TipRanks reiterated a Hold rating yesterday.
In a report released yesterday, Steven Wheen from Jarden maintained a Buy rating on Regis Healthcare Ltd., with a price target of A$8.50.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wheen covers the Healthcare sector, focusing on stocks such as Regis Healthcare Ltd., Integral Diagnostics Ltd., and Cochlear . According to TipRanks, Wheen has an average return of 9.0% and a 47.46% success rate on recommended stocks.
In addition to Jarden, Regis Healthcare Ltd. also received a Buy from Ord Minnett’s Tom Godfrey in a report issued on February 24. However, yesterday, TipRanks – OpenAI reiterated a Hold rating on Regis Healthcare Ltd. (ASX: REG).